In September 2022, the US Food and Drug Administration (FDA) approved Sotyktu (deucravacitinib; Bristol-Myers Squibb Company), a tyrosine kinase 2 (TYK2) inhibitor, for the treatment of moderate to ...

Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...

Working on fast cars has been Rogelio "Al" Castro's lifelong passion. Now, in retirement, he loves to take his grandkids to the speedway and tell them what it was like when he worked in the pit - the ...

Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, announced new Phase 3b topline Week 16 results from Cohort A of the VISIBLE trial, the first prospective, large-scale, randomized-controlled ...

Please provide your email address to receive an email when new articles are posted on . At week 16, 49.4% of the tildrakizumab group achieved clearance or near clearance of their scalp psoriasis vs. 7 ...

Plaque PsO is an immune-mediated disease resulting in the overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful. It is estimated that eight million Americans ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

TUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and body ...

Findings showed 64.7% of icotrokinra-treated patients achieved IGA scores 0/1 and 49.6% achieved PASI 90 compared with 8.3% and 4.4% of those on placebo, respectively. Topline results were announced ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ...